share_log

Institutional Investors in Vera Therapeutics, Inc. (NASDAQ:VERA) Lost 9.3% Last Week but Have Reaped the Benefits of Longer-term Growth

Institutional Investors in Vera Therapeutics, Inc. (NASDAQ:VERA) Lost 9.3% Last Week but Have Reaped the Benefits of Longer-term Growth

Vera Therapeutics, Inc.(纳斯达克股票代码:VERA)的机构投资者上周下跌了9.3%,但已经从长期增长中受益
Simply Wall St ·  05/13 09:17

Key Insights

关键见解

  • Significantly high institutional ownership implies Vera Therapeutics' stock price is sensitive to their trading actions
  • A total of 9 investors have a majority stake in the company with 52% ownership
  • Insiders have sold recently
  • 高机构所有权意味着Vera Therapeutics的股价对其交易行为很敏感
  • 共有9名投资者拥有该公司的多数股权,拥有52%的所有权
  • 业内人士最近卖出了

A look at the shareholders of Vera Therapeutics, Inc. (NASDAQ:VERA) can tell us which group is most powerful. With 62% stake, institutions possess the maximum shares in the company. Put another way, the group faces the maximum upside potential (or downside risk).

看看Vera Therapeutics, Inc.(纳斯达克股票代码:VERA)的股东可以告诉我们哪个集团最强大。机构拥有62%的股份,是公司的最大股份。换句话说,该集团面临最大的上行潜力(或下行风险)。

Institutional investors endured the highest losses after the company's market cap fell by US$219m last week. Still, the 418% one-year gains may have helped mitigate their overall losses. But they would probably be wary of future losses.

上周该公司的市值下降2.19亿美元后,机构投资者遭受了最大的损失。尽管如此,418%的一年期涨幅可能有助于减轻他们的总体亏损。但是他们可能会对未来的损失保持警惕。

In the chart below, we zoom in on the different ownership groups of Vera Therapeutics.

在下图中,我们放大了Vera Therapeutics的不同所有权群体。

ownership-breakdown
NasdaqGM:VERA Ownership Breakdown May 13th 2024
纳斯达克通用汽车:VERA 所有权明细 2024 年 5 月 13 日

What Does The Institutional Ownership Tell Us About Vera Therapeutics?

关于Vera Therapeutics,机构所有权告诉我们什么?

Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.

机构投资者通常将自己的回报与常见指数的回报进行比较。因此,他们通常会考虑收购相关基准指数中包含的大型公司。

As you can see, institutional investors have a fair amount of stake in Vera Therapeutics. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Vera Therapeutics' historic earnings and revenue below, but keep in mind there's always more to the story.

如你所见,机构投资者持有Vera Therapeutics的大量股份。这意味着在这些机构工作的分析师已经看过这只股票,他们很喜欢。但是就像其他人一样,他们可能错了。当多家机构拥有一只股票时,总是存在处于 “拥挤交易” 的风险。当这样的交易出错时,多方可能会竞相快速出售股票。对于没有增长历史的公司,这种风险更高。你可以在下面看到Vera Therapeutics的历史收益和收入,但请记住,故事总是有更多内容。

earnings-and-revenue-growth
NasdaqGM:VERA Earnings and Revenue Growth May 13th 2024
纳斯达克通用汽车公司:VERA 收益和收入增长 2024 年 5 月 13 日

Investors should note that institutions actually own more than half the company, so they can collectively wield significant power. Our data indicates that hedge funds own 8.0% of Vera Therapeutics. That catches my attention because hedge funds sometimes try to influence management, or bring about changes that will create near term value for shareholders. Longitude Capital Management Co., LLC is currently the largest shareholder, with 9.4% of shares outstanding. Commodore Capital LP is the second largest shareholder owning 8.1% of common stock, and Kynam Capital Management, LP holds about 6.7% of the company stock.

投资者应注意,机构实际上拥有公司一半以上的股份,因此它们可以共同行使巨大的权力。我们的数据显示,对冲基金拥有Vera Therapeutics8.0%的股份。这引起了我的注意,因为对冲基金有时会试图影响管理层,或者带来能够为股东创造短期价值的变革。经纬资本管理有限公司目前是最大股东,已发行股份的9.4%。Commodore Capital LP是第二大股东,拥有8.1%的普通股,Kynam Capital Management, LP持有该公司约6.7%的股份。

We also observed that the top 9 shareholders account for more than half of the share register, with a few smaller shareholders to balance the interests of the larger ones to a certain extent.

我们还观察到,前9名股东占股票登记册的一半以上,少数规模较小的股东可以在一定程度上平衡大股东的利益。

While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. Quite a few analysts cover the stock, so you could look into forecast growth quite easily.

虽然研究公司的机构所有权数据是有意义的,但研究分析师的情绪以了解风向哪个方向吹来也是有意义的。有不少分析师报道了该股,因此你可以很容易地研究预测的增长。

Insider Ownership Of Vera Therapeutics

维拉疗法的内部所有权

The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.

不同国家对内部人员的定义可能略有不同,但董事会成员总是计算在内。公司管理层经营业务,但首席执行官将向董事会负责,即使他或她是董事会成员。

Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.

当内部所有权表明领导层像公司的真正所有者一样思考时,内部所有权是积极的。但是,高度的内部所有权也可以赋予公司内部的一小部分人巨大的权力。在某些情况下,这可能是负面的。

Our most recent data indicates that insiders own less than 1% of Vera Therapeutics, Inc.. But they may have an indirect interest through a corporate structure that we haven't picked up on. It is a pretty big company, so it would be possible for board members to own a meaningful interest in the company, without owning much of a proportional interest. In this case, they own around US$13m worth of shares (at current prices). It is good to see board members owning shares, but it might be worth checking if those insiders have been buying.

我们的最新数据显示,内部人士拥有的Vera Therapeutics, Inc.不到1%的股份。但是,他们可能会通过我们尚未采用的公司结构获得间接利益。这是一家相当大的公司,因此董事会成员有可能在不拥有太多比例权益的情况下拥有该公司的有意义的权益。在这种情况下,他们拥有价值约1300万美元的股票(按当前价格计算)。很高兴看到董事会成员拥有股票,但可能值得检查一下这些内部人士是否在买入。

General Public Ownership

一般公有制

With a 11% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Vera Therapeutics. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.

Vera Therapeutics拥有11%的所有权,主要由个人投资者组成的公众对Vera Therapeutics有一定程度的影响力。这种所有权规模虽然可观,但如果决策与其他大股东不同步,可能不足以改变公司政策。

Private Equity Ownership

私募股权所有权

With a stake of 15%, private equity firms could influence the Vera Therapeutics board. Sometimes we see private equity stick around for the long term, but generally speaking they have a shorter investment horizon and -- as the name suggests -- don't invest in public companies much. After some time they may look to sell and redeploy capital elsewhere.

私募股权公司持有15%的股份,可能会影响Vera Therapeutics的董事会。有时我们会看到私募股权长期存在,但总的来说,它们的投资期限较短,而且顾名思义,对上市公司的投资并不多。一段时间后,他们可能会考虑出售资本并将其重新部署到其他地方。

Private Company Ownership

私人公司所有权

We can see that Private Companies own 3.5%, of the shares on issue. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it's hard to draw any broad stroke conclusions, it is worth noting as an area for further research.

我们可以看到,私人公司拥有已发行股份的3.5%。私营公司可能是关联方。有时,内部人士通过控股私营公司而对上市公司拥有权益,而不是以个人身份拥有权益。尽管很难得出任何宽泛的结论,但值得注意的是,这是一个需要进一步研究的领域。

Next Steps:

后续步骤:

It's always worth thinking about the different groups who own shares in a company. But to understand Vera Therapeutics better, we need to consider many other factors. Case in point: We've spotted 4 warning signs for Vera Therapeutics you should be aware of, and 1 of them is concerning.

拥有公司股份的不同群体总是值得考虑的。但是,为了更好地了解Vera Therapeutics,我们需要考虑许多其他因素。一个很好的例子:我们发现了你应该注意的4个Vera Therapeutics警告信号,其中一个令人担忧。

If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.

如果你像我一样,你可能需要考虑这家公司是会成长还是会萎缩。幸运的是,您可以查看这份免费报告,其中显示了分析师对其未来的预测。

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

注意:本文中的数字是使用过去十二个月的数据计算得出的,这些数据是指截至财务报表日期当月最后一天的12个月期间。这可能与全年年度报告数据不一致。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发